British biotechnology company TRIMTECH Therapeutics has secured an additional £11 million in seed financing, bringing its total seed round to £35 million.
The extension was led by Johnson & Johnson Innovation – JJDC and BGF, which join an investor syndicate that includes Cambridge Innovation Capital, Pfizer Ventures, Eli Lilly, M Ventures, MP Healthcare Venture Management, DDF and Cambridge Enterprise Ventures.
Founded on decades of academic research into the protein TRIM21, TRIMTECH is developing small-molecule therapies designed to selectively degrade toxic protein aggregates linked to Alzheimer’s disease and other neurodegenerative disorders.
The company’s proprietary TRIMTAC and TRIMGLUE platforms aim to eliminate harmful protein aggregates and oligomers while preserving the healthy forms of those same proteins, a distinction that could help maintain normal cellular function. The approach represents a new avenue in the rapidly expanding field of targeted protein degradation.
TRIMTECH said the new capital will be used to advance its portfolio of central nervous system-penetrant degraders and further develop its technology platforms. The company believes its approach could unlock treatments for diseases affecting large patient populations, including Alzheimer’s, which impacts more than 55 million people worldwide.
Following the financing, representatives from JJDC and BGF will join TRIMTECH’s board as non-executive directors.
There is a growing interest from major pharmaceutical and life sciences investors in next-generation therapies for neurodegenerative diseases, a field where effective treatment options remain limited despite decades of research.
